Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition

Nature Communications

Volumn 7, Issue , 2016, Pages

  Burger, Jan A ^a   Landau, Dan A ^b,c,d   Taylor Weiner, Amaro ^b   Bozic, Ivana ^e,f   Zhang, Huidan ^g,h   Sarosiek, Kristopher ⁱ   Wang, Lili ⁱ   Stewart, Chip ^b   Fan, Jean ^j   Hoellenriegel, Julia ^a   Sivina, Mariela ^a   Dubuc, Adrian M ^k   Fraser, Cameron ⁱ   Han, Yulong ^l   Li, Shuqiang ^m   Livak, Kenneth J ^m   Zou, Lihua ^b   Wan, Youzhong ⁱ   Konoplev, Sergej ^a   Sougnez, Carrie ^b   Brown, Jennifer R ⁱ   Abruzzo, Lynne V ^a   Carter, Scott L ^b   Michael, J Keating ^a   Davids, Matthew S ⁱ   Wierda, William G ^a   Cibulskis, Kristian ^b   Zenz, Thorsten ⁿ   Werner, Lillian ⁱ   Cin, Paola Dal ^k   Kharchencko, Peter ^j   Neuberg, Donna ⁱ   Kantarjian, Hagop ^a   Lander, Eric ^b   Gabriel, Stacey ^b   O'Brien, Susan ^a   Letai, Anthony ⁱ   Weitz, David A ^g   Nowak, Martin A ^e,f   Getz, Gad ^b   Wu, Catherine J ^b,i,k   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d NEW YORK GENOME CENTER   (United States)

^e HARVARD UNIVERSITY   (United States)

^f HARVARD UNIVERSITY   (United States)

^g HARVARD UNIVERSITY   (United States)

^h CHINA MEDICAL UNIVERSITY   (China)

ⁱ DANA FARBER CANCER INSTITUTE   (United States)

^j Harvard Medical School Center for Biomedical Informatics   (United States)

^k BRIGHAM AND WOMEN S HOSPITAL   (United States)

^l XI'AN JIAOTONG UNIVERSITY   (China)

^m FLUIDIGM CORPORATION   (United States)

ⁿ GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BRUTON TYROSINE KINASE; IBRUTINIB; AGAMMAGLOBULINAEMIA TYROSINE KINASE; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

BIOTECHNOLOGY; CANCER; DISEASE TREATMENT; ENZYME; INHIBITION; INHIBITOR; MUTATION;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER RECURRENCE; CANCER RESISTANCE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLONAL EVOLUTION; DRUG RESPONSE; EIF2A GENE; ENZYME INHIBITION; EP300 GENE; FEMALE; GENE; GENE MUTATION; HAPLOINSUFFICIENCY; HISTIOCYTIC SARCOMA; HUMAN; HUMAN TISSUE; LEUKOCYTE COUNT; MALE; MICROFLUIDIC ANALYSIS; MLL2 GENE; TUMOR DIFFERENTIATION; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CASE REPORT; CELL TRANSDIFFERENTIATION; DRUG RESISTANCE; GENETIC SELECTION; GENETICS; MIDDLE AGED; MUTATION; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED, 80 AND OVER; APOPTOSIS; CELL TRANSDIFFERENTIATION; CLONAL EVOLUTION; DRUG RESISTANCE, NEOPLASM; FEMALE; HISTIOCYTIC SARCOMA; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; PROTEIN-TYROSINE KINASES; PYRAZOLES; PYRIMIDINES; SELECTION, GENETIC;

EID: 84970003155     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms11589     Document Type: Article

References (45)

1. Burger, J. A. & Chiorazzi, N. B cell receptor signaling in chronic lymphocytic leukemia. Trends Immunol. 34, 592-601 (2013).
2. Friedberg, J. W. et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 115, 2578-2585 (2010).
3. Byrd, J. C. et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 369, 32-42 (2013).
4. Furman, R. R. et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 370, 997-1007 (2014).
5. Honigberg, L. A. et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc. Natl Acad. Sci. USA 107, 13075-13080 (2010).
6. Woyach, J. A. et al. Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. N. Engl. J. Med. 370, 2286-2294 (2014).
7. Furman, R. R. et al. Ibrutinib resistance in chronic lymphocytic leukemia. N. Engl. J. Med. 370, 2352-2354 (2014).
8. Landau, D. A. et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 152, 714-726 (2013).
9. Thompson, P. A. et al. Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens. Cancer 121, 3612-3621 (2015).
10. Burger, J. A. et al. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: A single-Arm, phase 2 study. Lancet Oncol. 15, 1090-1099 (2014).
11. Zhou, Q. et al. A hypermorphic missense mutation in PLCG2, encoding phospholipase Cgamma2, causes a dominantly inherited autoinflammatory disease with immunodeficiency. Am. J. Hum. Genet. 91, 713-720 (2012).
12. Messmer, B. T. et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J. Clin. Invest. 115, 755-764 (2005).
13. Chiron, D. et al. Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma. Cancer Discov. 4, 1022-1035 (2014).
14. Fritsch, R. M., Schneider, G., Saur, D., Scheibel, M. & Schmid, R. M. Translational repression of MCL-1 couples stress-induced eIF2 alpha phosphorylation to mitochondrial apoptosis initiation. J. Biol. Chem. 282, 22551-22562 (2007).
15. Lawrence, M. S. et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505, 495-501 (2014).
16. Landau, D. A. et al. Mutations driving CLL and their evolution in progression and relapse. Nature 526, 525-530 (2015).
17. Ljungstrom, V. et al. Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations. Blood 127, 1007-1016 (2016).
18. Rubio-Moscardo, F. et al. Characterization of 8p21.3 chromosomal deletions in B-cell lymphoma: TRAIL-R1 and TRAIL-R2 as candidate dosage-dependent tumor suppressor genes. Blood 106, 3214-3222 (2005).
19. Herbeuval, J. P. et al. HAART reduces death ligand but not death receptors in lymphoid tissue of HIV-infected patients and simian immunodeficiency virus-infected macaques. AIDS 23, 35-40 (2009).
20. Secchiero, P. et al. Aberrant expression of TRAIL in B chronic lymphocytic leukemia (B-CLL) cells. J. Cell Physiol. 205, 246-252 (2005).
21. Shah, N. P. et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2, 117-125 (2002).
22. Bozic, I. & Nowak, M. A. Timing and heterogeneity of mutations associated with drug resistance in metastatic cancers. Proc. Natl Acad. Sci. USA 111, 15964-15968 (2014).
23. Komarova, N. L., Burger, J. A. & Wodarz, D. Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL). Proc. Natl Acad. Sci. USA 111, 13906-13911 (2014).
24. Brown, J. R. et al. Integrative genomic analysis implicates gain of PIK3CA at 3q26 and MYC at 8q24 in chronic lymphocytic leukemia. Clin. Cancer Res. 18, 3791-3802 (2012).
25. Forconi, F. et al. Genome-wide DNA analysis identifies recurrent imbalances predicting outcome in chronic lymphocytic leukaemia with 17p deletion. Br. J. Haematol. 143, 532-536 (2008).
26. Shao, H. et al. Clonally related histiocyticdendritic cell sarcoma and chronic lymphocytic leukemiasmall lymphocytic lymphoma: A study of seven cases. Mod. Pathol. 24, 1421-1432 (2011).
27. Xie, H., Ye, M., Feng, R. & Graf, T. Stepwise reprogramming of B cells into macrophages. Cell 117, 663-676 (2004).
28. Chen, W. et al. Langerhans cell sarcoma arising from chronic lymphocytic lymphomasmall lymphocytic leukemia: lineage analysis and BRAF V600E mutation study. N. Am. J. Med. Sci. 5, 386-391 (2013).
29. Buser, L. et al. Unique composite hematolymphoid tumor consisting of a pro-T lymphoblastic lymphoma and an indeterminate dendritic cell tumor: evidence for divergent common progenitor cell differentiation. Pathobiology 81, 199-205 (2014).
30. Oh, H., Siano, B. & Diamond, S. Neutrophil isolation protocol. J. Vis. Exp. 17, 745 (2008).
31. Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31, 213-219 (2013).
32. Robinson, J. T. et al. Integrative genomics viewer. Nat. Biotechnol. 29, 24-26 (2011).
33. Carter, S., Meyerson, M. & Getz, G. Accurate estimation of homologue-specific DNA concentration-ratios in cancer samples allows long-range haplotyping. Nat. Preced. pp 59-87 (2011).
34. Carter, S. L. et al. Absolute quantification of somatic DNA alterations in human cancer. Nat. Biotechnol. 30, 413-421 (2012).
35. Berger, M. F. et al. The genomic complexity of primary human prostate cancer. Nature 470, 214-220 (2011).
36. Chapman, M. A. et al. Initial genome sequencing and analysis of multiple myeloma. Nature 471, 467-472 (2011).
37. Fisher, S. et al. A scalable, fully automated process for construction of sequence-ready human exome targeted capture libraries. Genome Biol. 12, R1 (2011).
38. Li, H. & Durbin, R. Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics 26, 589-595 (2010).
39. Lohr, J. G. et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc. Natl Acad. Sci. USA 109, 3879-3884 (2012).
40. McFadden, D. G. et al. Genetic and clonal dissection of murine small cell lung carcinoma progression by genome sequencing. Cell 156, 1298-1311 (2014).
41. Herman, S. E. et al. Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study. Leukemia 28, 2188-2196 (2014).
42. Qin, D., Xia, Y. & Whitesides, G. M. Soft lithography for micro-And nanoscale patterning. Nat. Protoc. 5, 491-502 (2010).
43. Link, D. R. et al. Electric control of droplets in microfluidic devices. Angew. Chem. Int. Ed. Engl. 45, 2556-2560 (2006).
44. Livak, K. J. et al. Methods for qPCR gene expression profiling applied to 1440 lymphoblastoid single cells. Methods 59, 71-79 (2013).
45. Marras, S., Vargas-Gold, D., Tyagi, S. & Kramer, F. R. Highly selective nucleic acid amplification primers. U. S. Patent Application 20150361475 (2015).